Duncan Kennedy
Geen lopende functies
Vermogen: 16 485 $ op 31-03-2024
Profiel
Duncan Kennedy served as the Chief Financial Officer & Director at BTG Ltd.
from 2018 to 2019 and as the Chief Financial Officer & Executive Director at James Fisher & Sons Plc from 2021 to 2023.
Prior to these roles, he obtained an undergraduate degree from the University of Durham.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-12-2022 | 5 000 ( 0.01% ) | 16 485 $ | 31-03-2024 |
Eerdere bekende functies van Duncan Kennedy
| Bedrijven | Functie | Einde |
|---|---|---|
| JAMES FISHER AND SONS PLC | Director of Finance/CFO | 01-12-2023 |
| BTG | Director of Finance/CFO | 31-12-2019 |
Opleiding van Duncan Kennedy
| University of Durham | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| JAMES FISHER AND SONS PLC | Transportation |
| Bedrijven in privébezit | 1 |
|---|---|
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
